Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Acquisitions & Divestments: 2022-2024

Historic Change in Acquisitions & Divestments for Immuneering (IMRX) over the last 3 years, with Dec 2024 value amounting to $31.9 million.

  • Immuneering's Change in Acquisitions & Divestments fell 71.13% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.0 million, marking a year-over-year decrease of 2.52%. This contributed to the annual value of $31.9 million for FY2024, which is 38.95% down from last year.
  • Immuneering's Change in Acquisitions & Divestments amounted to $31.9 million in FY2024, which was down 38.95% from $52.3 million recorded in FY2023.
  • Over the past 5 years, Immuneering's Change in Acquisitions & Divestments peaked at $92.7 million during FY2022, and registered a low of $31.9 million during FY2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $59.0 million, with a median of $52.3 million in 2023.
  • Data for Immuneering's Change in Acquisitions & Divestments shows a maximum YoY plummeted of 43.57% (in 2023) over the last 5 years.
  • Immuneering's Change in Acquisitions & Divestments (Yearly) stood at $92.7 million in 2022, then plummeted by 43.57% to $52.3 million in 2023, then tumbled by 38.95% to $31.9 million in 2024.